Patent Economics

When natural compounds cannot be patented, pharmaceutical incentives to fund clinical trials are minimal and incentives to cast doubt are significant. Berberine's absence from mainstream medical protocols reflects patent economics rather than a lack of efficacy. Over 41 active patents exist on berberine-related formulations, demonstrating serious commercial and research interest despite the compound's natural origin. Berberine cannot receive a full patent as a natural compound, limiting pharmaceutical companies' financial incentive to fund large-scale trials. Metformin, a blockbuster diabetes drug often compared to berberine, carries a black box warning for serious documented side effects.